Neuland Laboratories Limited
NEULANDLAB.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$268.42B
Close$
$8595.85
56.9% downside
Current Fair Value
56.9% downsideOvervalued by 56.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $268.42 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $34.00 (0.16%) |
| Earnings per Share | $283.71 |
| Beta | -0.32 |
| Outstanding Shares | 12,829,983 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 53.84 |
|---|---|
| PEG | 5.59 |
| Price to Sales | 10.8 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$60.45
Average shareholder expectationRevenue Estimate
$5.01 B
Average shareholder expectationNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$33.84
Average shareholder expectationRevenue Estimate
$5.14 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Neuland Laboratories Limited
1,643 employees
CEO: Davuluri Saharsh Rao Neuland Laboratories Limited functions as a global developer and provider of active pharmaceutical ingredients (APIs), with a significant market presence in India, Europe, the United States, and other international territories. These vit...